Thread by @Biotech2k1

Looking at my Onco-Pathway Companies:

This is one of my oldest investment themes. Its been the most profitable, yet most frustrating as every time I get great companies they get bought up on me and I have to start over. That why I have 5 now.

Here is where I stand.

$BPMC 3.34%
$TPTX 5.51%
$MRTX 3.34%
$RVMD 2.76%
$ERAS 2.76%

This theme makes up 17.71% of my portfolio

$BPMC is my oldest and longest held core position. They have amazing management and a very strong pipeline that keeps on coming up with new ideas. My worst complaint is it never crashes for me to add to it anymore. Once in a while I get lucky to add some.

$TPTX is another core position to me. I had sold it all in Jan at $130 as it was way over hyped on KRAS. Now I am buying it back at less then half that price. They still have a lot of early programs to validate, but its just too cheap now with all the potential they have.

$MRTX has been a staple in my portfolio since LOXO was bought out on me. Its my top pick for KRAS as of now. They have a ton of competition in that space. Its been very well loved so I welcome the pull back suddenly to get some cheaper shares.

$RVMD is another early stage KRAS company. They are focused on the entire MAPK pathway. They are targeting RAS in the on form which makes more sense in theory. Now we need to see the actual data.

$ERAS is the management team from my first buyout of RXDX. They are back and doing KRAS and the entire MAPK pathway. They have less validation on science then $RVMD, but they have a proven winning management that earns them a spot with me.

My top 3 position here have been here for years and they aren't going anywhere as my shares are free at this point. I would just look for great pull backs to add a little.

My 2 newbies are exciting, but not validated. They are all trading around cost so I could triage this section of my portfolio down to 3 companies if the market really got ugly.